Published in Toxicol Sci on April 29, 2009
EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals. Endocr Rev (2015) 2.51
Endocrine-disrupting chemicals: associated disorders and mechanisms of action. J Environ Public Health (2012) 1.40
Environmental endocrine disruptors promote adipogenesis in the 3T3-L1 cell line through glucocorticoid receptor activation. Obesity (Silver Spring) (2009) 1.38
Adipocytes under assault: environmental disruption of adipose physiology. Biochim Biophys Acta (2013) 0.89
Bacterial biosensors for screening isoform-selective ligands for human thyroid receptors α-1 and β-1. FEBS Open Bio (2012) 0.78
Identification of thyroid hormone response elements in vivo using mice expressing a tagged thyroid hormone receptor α1. Biosci Rep (2013) 0.75
Concerted peptide trimming by human ERAP1 and ERAP2 aminopeptidase complexes in the endoplasmic reticulum. Nat Immunol (2005) 3.39
Mutations in SECISBP2 result in abnormal thyroid hormone metabolism. Nat Genet (2005) 2.69
Gene disruption discloses role of selenoprotein P in selenium delivery to target tissues. Biochem J (2003) 2.30
Evidence for extrathyroidal formation of 3-iodothyronamine in humans as provided by a novel monoclonal antibody-based chemiluminescent serum immunoassay. J Clin Endocrinol Metab (2011) 1.79
Strong associations of 25-hydroxyvitamin D concentrations with all-cause, cardiovascular, cancer, and respiratory disease mortality in a large cohort study. Am J Clin Nutr (2013) 1.62
Selenoprotein-related disease in a young girl caused by nonsense mutations in the SBP2 gene. J Clin Endocrinol Metab (2010) 1.59
Selenium and brain function: a poorly recognized liaison. Brain Res Brain Res Rev (2004) 1.42
Neuronal selenoprotein expression is required for interneuron development and prevents seizures and neurodegeneration. FASEB J (2009) 1.41
Welcome to thyroid research. Thyroid Res (2008) 1.40
Serum selenium deficiency in patients with hematological malignancies: is a supplementation study mandatory? Acta Haematol (2014) 1.37
Hepatically derived selenoprotein P is a key factor for kidney but not for brain selenium supply. Biochem J (2005) 1.36
Evaluation of the association between persistent organic pollutants (POPs) and diabetes in epidemiological studies: a national toxicology program workshop review. Environ Health Perspect (2013) 1.36
Increased risk of thyroid pathology in patients with thyroid hemiagenesis: results of a large cohort case-control study. Eur J Endocrinol (2009) 1.28
Neuronal 3',3,5-triiodothyronine (T3) uptake and behavioral phenotype of mice deficient in Mct8, the neuronal T3 transporter mutated in Allan-Herndon-Dudley syndrome. J Neurosci (2009) 1.28
New assay for the measurement of selenoprotein P as a sepsis biomarker from serum. J Trace Elem Med Biol (2008) 1.24
Effects of selenium status and polymorphisms in selenoprotein genes on prostate cancer risk in a prospective study of European men. Cancer Epidemiol Biomarkers Prev (2010) 1.23
Efficient selenium transfer from mother to offspring in selenoprotein-P-deficient mice enables dose-dependent rescue of phenotypes associated with selenium deficiency. Biochem J (2004) 1.19
The impact of iron and selenium deficiencies on iodine and thyroid metabolism: biochemistry and relevance to public health. Thyroid (2002) 1.17
Selenium controls the sex-specific immune response and selenoprotein expression during the acute-phase response in mice. Biochem J (2010) 1.17
Determinants of selenium status in healthy adults. Nutr J (2011) 1.16
Hepatic selenoprotein P (SePP) expression restores selenium transport and prevents infertility and motor-incoordination in Sepp-knockout mice. Biochem J (2008) 1.16
Four selenoproteins, protein biosynthesis, and Wnt signalling are particularly sensitive to limited selenium intake in mouse colon. Mol Nutr Food Res (2009) 1.12
Selenium in sepsis--substitution, supplementation or pro-oxidative bolus? Crit Care (2014) 1.10
Oh, no--equations! Reanalysis of the data reveal even stronger associations between Hashimoto's thyroiditis and differentiated thyroid cancer. Thyroid (2015) 1.06
Development of a validated liquid chromatography/tandem mass spectrometry method for the distinction of thyronine and thyronamine constitutional isomers and for the identification of new deiodinase substrates. Rapid Commun Mass Spectrom (2008) 1.05
On the importance of selenium and iodine metabolism for thyroid hormone biosynthesis and human health. Mol Nutr Food Res (2008) 1.03
Mutation of megalin leads to urinary loss of selenoprotein P and selenium deficiency in serum, liver, kidneys and brain. Biochem J (2010) 1.02
Activation of mitochondrial energy metabolism protects against cardiac failure. Aging (Albany NY) (2010) 1.02
Developmental and cell type-specific expression of thyroid hormone transporters in the mouse brain and in primary brain cells. Glia (2010) 1.01
Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology. Int J Radiat Oncol Biol Phys (2010) 1.01
Comparison of different selenocompounds with respect to nutritional value vs. toxicity using liver cells in culture. J Nutr Biochem (2010) 1.00
Expression profiling and genetic alterations of the selenoproteins GI-GPx and SePP in colorectal carcinogenesis. Nutr Cancer (2004) 1.00
Serum 25-hydroxyvitamin d and cancer risk in older adults: results from a large German prospective cohort study. Cancer Epidemiol Biomarkers Prev (2013) 0.99
Circulating levels of peroxiredoxin 4 as a novel biomarker of oxidative stress in patients with sepsis. Shock (2011) 0.99
The neurobiology of selenium: lessons from transgenic mice. J Nutr (2004) 0.98
3,5-Diiodo-L-thyronine (3,5-t2) exerts thyromimetic effects on hypothalamus-pituitary-thyroid axis, body composition, and energy metabolism in male diet-induced obese mice. Endocrinology (2015) 0.98
Selenium-dependent pre- and posttranscriptional mechanisms are responsible for sexual dimorphic expression of selenoproteins in murine tissues. Endocrinology (2006) 0.98
Selenium in oncology: from chemistry to clinics. Molecules (2009) 0.97
Copeptin and peroxiredoxin-4 independently predict mortality in patients with nonspecific complaints presenting to the emergency department. Acad Emerg Med (2011) 0.97
Essential molecular determinants for thyroid hormone transport and first structural implications for monocarboxylate transporter 8. J Biol Chem (2010) 0.97
Standardization of misleading immunoassay based 25-hydroxyvitamin D levels with liquid chromatography tandem-mass spectrometry in a large cohort study. PLoS One (2012) 0.96
Selenium or no selenium--that is the question in tumor patients: a new controversy. Integr Cancer Ther (2010) 0.96
The ultraviolet filter benzophenone 2 interferes with the thyroid hormone axis in rats and is a potent in vitro inhibitor of human recombinant thyroid peroxidase. Endocrinology (2007) 0.96
Endocrine active compounds affect thyrotropin and thyroid hormone levels in serum as well as endpoints of thyroid hormone action in liver, heart and kidney. Toxicology (2004) 0.96
Detection of 3,5-diiodothyronine in sera of patients with altered thyroid status using a new monoclonal antibody-based chemiluminescence immunoassay. Thyroid (2014) 0.95
Differential responses to selenomethionine supplementation by sex and genotype in healthy adults. Br J Nutr (2011) 0.94
Aminoaciduria, but normal thyroid hormone levels and signalling, in mice lacking the amino acid and thyroid hormone transporter Slc7a8. Biochem J (2011) 0.94
CD82, and CD63 in thyroid cancer. Int J Mol Med (2004) 0.94
Surface translocation and tri-iodothyronine uptake of mutant MCT8 proteins are cell type-dependent. J Mol Endocrinol (2009) 0.93
Secisbp2 is essential for embryonic development and enhances selenoprotein expression. Antioxid Redox Signal (2014) 0.93
Autoantibodies to the IGF1 receptor in Graves' orbitopathy. J Clin Endocrinol Metab (2012) 0.93
Selenium and goiter prevalence in borderline iodine sufficiency. Eur J Endocrinol (2006) 0.93
A complex DNA-repeat structure within the Selenoprotein P promoter contains a functionally relevant polymorphism and is genetically unstable under conditions of mismatch repair deficiency. Eur J Hum Genet (2002) 0.93
Transgenic mice expressing small interfering RNA against Gata4 point to a crucial role of Gata4 in the heart and gonads. J Mol Endocrinol (2009) 0.92
Selenoprotein-P is down-regulated in prostate cancer, which results in lack of protection against oxidative damage. Prostate (2010) 0.92
Down-regulation of the hepatic selenoprotein biosynthesis machinery impairs selenium metabolism during the acute phase response in mice. FASEB J (2009) 0.92
Proinflammatory cytokines inhibit the expression and function of human type I 5'-deiodinase in HepG2 hepatocarcinoma cells. Eur J Endocrinol (2002) 0.91
V2 vasopressin receptor deficiency causes changes in expression and function of renal and hypothalamic components involved in electrolyte and water homeostasis. Am J Physiol Renal Physiol (2008) 0.91
Selenium supplementation fails to correct the selenoprotein synthesis defect in subjects with SBP2 gene mutations. Thyroid (2009) 0.90
Proteomic approach reveals novel targets for retinoic acid-mediated therapy of thyroid carcinoma. Mol Cell Endocrinol (2010) 0.90
Selenium status, thyroid volume, and multiple nodule formation in an area with mild iodine deficiency. Eur J Endocrinol (2011) 0.89
Hepatic deiodinase activity is dispensable for the maintenance of normal circulating thyroid hormone levels in mice. Biochem Biophys Res Commun (2005) 0.89
Selenium status is associated with colorectal cancer risk in the European prospective investigation of cancer and nutrition cohort. Int J Cancer (2014) 0.89
Synthesis and metabolism of thyroid hormones is preferentially maintained in selenium-deficient transgenic mice. Endocrinology (2005) 0.89
The choice of biomarkers determines the selenium status in young German vegans and vegetarians. Br J Nutr (2010) 0.88
Retinoic acid-mediated down-regulation of ENO1/MBP-1 gene products caused decreased invasiveness of the follicular thyroid carcinoma cell lines. J Mol Endocrinol (2008) 0.87
Differential modulation of Beta-adrenergic receptor signaling by trace amine-associated receptor 1 agonists. PLoS One (2011) 0.87
Selenite supplementation in euthyroid subjects with thyroid peroxidase antibodies. Clin Endocrinol (Oxf) (2013) 0.87
Endocrine disruptors and the thyroid gland--a combined in vitro and in vivo analysis of potential new biomarkers. Environ Health Perspect (2007) 0.87
Mechanism-based testing strategy using in vitro approaches for identification of thyroid hormone disrupting chemicals. Toxicol In Vitro (2013) 0.87
Serum selenium is low in newly diagnosed Graves' disease: a population-based study. Clin Endocrinol (Oxf) (2013) 0.87
Human thyroid carcinoma cell lines show different retinoic acid receptor repertoires and retinoid responses. Eur J Endocrinol (2004) 0.87
Inhibition of xanthine oxidase reduces wasting and improves outcome in a rat model of cancer cachexia. Int J Cancer (2012) 0.87
Think globally: act locally. New insights into the local regulation of thyroid hormone availability challenge long accepted dogmas. Mol Cell Endocrinol (2008) 0.86
Function of thyroid hormone transporters in the central nervous system. Biochim Biophys Acta (2012) 0.86
Selenoproteins of the thyroid gland: expression, localization and possible function of glutathione peroxidase 3. Biol Chem (2007) 0.86
Insights into molecular properties of the human monocarboxylate transporter 8 by combining functional with structural information. Thyroid Res (2011) 0.86
Reduced serum selenoprotein P concentrations in German prostate cancer patients. Cancer Epidemiol Biomarkers Prev (2009) 0.86
Selenoprotein P status correlates to cancer-specific mortality in renal cancer patients. PLoS One (2012) 0.85
Plasma bile acids are associated with energy expenditure and thyroid function in humans. J Clin Endocrinol Metab (2011) 0.85